2,5-Dimethoxy-4-ethoxyamphetamine
| Clinical data | |
|---|---|
| Other names | 2,5-Dimethoxy-4-ethoxyamphetamine; 4-Ethoxy-2,5-dimethoxyamphetamine; MEM |
| Routes of administration | Oral |
| Drug class | Serotonin receptor agonist; Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 10–14 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H21NO3 |
| Molar mass | 239.315 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
2,5-Dimethoxy-4-ethoxyamphetamine (MEM) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It was first described by Alexander Shulgin by 1968.